Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Embecta Corp. in the United States District Court for the District of New Jersey on behalf of investors who purchased Embecta common stock between November 25, 2025 and May 4, 2026. The complaint alleges that the company made materially false and misleading statements about its fiscal results and guidance, particularly regarding its pen needle business, which was described as "incredibly resolute" shortly before a disappointing earnings report. On May 5, 2026, Embecta reported second-quarter results below analyst expectations and cut its full-year 2026 guidance, citing a loss in the pen needle category and soft market volume, causing its share price to drop approximately 58% from $9.25 to $3.90. Investors have until August 17, 2026 to seek lead plaintiff appointment.
Embecta CorpClass action lawsuit alleging false statements about pen needle business and disappointing earnings causing 58% stock drop.